These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30296835)

  • 1. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
    Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
    Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
    Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose decitabine for refractory thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children: A pilot study.
    Liu N; Zhao FY; Liang J; Shang LP; Xu XJ
    Int Immunopharmacol; 2023 Feb; 115():109579. PubMed ID: 36577152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
    Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment CD34
    Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
    Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
    BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
    Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
    Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
    Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
    Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes.
    Cheok KPL; Chhetri R; Wee LYA; Friel O; Pham A; Salvi A; McRae S; Bardy P; Singhal D; Roxby DJ; Wood EM; Hiwase DK
    Transfusion; 2020 Oct; 60(10):2192-2198. PubMed ID: 32905635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases.
    Zhang K; Lian Y; Guan X; Hu Q; Lei L; Tao L; He D; Lin J; Hou Z; Ren L; Liu X; Ren Q; Pan L; Fei X; Xiong M; Wen S; Cao J
    Ann Hematol; 2020 Nov; 99(11):2539-2546. PubMed ID: 32939674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
    Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
    Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation.
    Thomas-Kaskel AK; Mattern D; Köhler G; Finke J; Behringer D
    Cytometry B Clin Cytom; 2007 Jul; 72(4):241-8. PubMed ID: 17266149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang H; Huang M; Zhao Y; Qi JQ; Chen C; Tang YQ; Qiu HY; Fu CC; Tang XW; Wu DP; Ruan CG; Han Y
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1678-1684. PubMed ID: 28642072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
    Zhou J; Wang J; Liu H; Zheng H; Ma L; Wang P; Yan S; Wu D; Fu C; Qiu H; Tang X; Jin Z; Han Y; Miao M
    Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(12):920-4. PubMed ID: 26081055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
    Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
    Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
    Al Ameri A; Jabbour E; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Shan J; Pierce S; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):237-41. PubMed ID: 21575929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT.
    Zhang XH; Wang QM; Zhang JM; Feng FE; Wang FR; Chen H; Zhang YY; Chen YH; Han W; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2015 Oct; 8():116. PubMed ID: 26497387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.
    Yoon JH; Jeon YW; Yahng SA; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Kim HJ; Lee S; Min CK; Cho SG; Kim Y; Kim DW; Lee JW; Han K; Min WS; Park CW; Kim M; Kim YJ
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):460-7. PubMed ID: 25460359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.